2-(dimethylamino)-6-methylaminobenzonitrile | 335640-44-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(dimethylamino)-6-methylaminobenzonitrile
• 英文别名: 2-(Dimethylamino)-6-(methylamino)benzonitrile
• CAS: 335640-44-3
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.233
• InChiKey: IBAGBHFAJNYENY-UHFFFAOYSA-N

物化性质

• 沸点：
  354.0±37.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  39.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(dimethylamino)-6-methylaminobenzonitrile 在 硫酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 5-Dimethylamino-1-methyl-1H-benzo[d][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship

  摘要：

  Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).

  DOI：

  10.1021/jm031044w
• 作为产物：
  描述：

  2,6-二氟苯腈 以 水 、 异丙醇 为溶剂， 反应 36.0h， 生成 2-(dimethylamino)-6-methylaminobenzonitrile
  参考文献：
  名称：

  Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship

  摘要：

  Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).

  DOI：

  10.1021/jm031044w

文献信息

• DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS
  申请人：Active Biotech AB

  公开号：EP1224172A1

  公开（公告）日：2002-07-24
• US6395750B1
  申请人：——

  公开号：US6395750B1

  公开（公告）日：2002-05-28
• US6605616B1
  申请人：——

  公开号：US6605616B1

  公开（公告）日：2003-08-12
• [EN] DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS<br/>[FR] MEDICAMENTS DE TRAITEMENT DE TUMEURS MALIGNES
  申请人：ACTIVE BIOTECH AB

  公开号：WO2001030758A1

  公开（公告）日：2001-05-03

  The invention relates to the use of compounds of general formula (I) or any tautomer, optical isomer or racemate thereof for the manufacturing of a medicament for the treatment of cancer. The invention also comprises novel compounds, pharmaceutical compositions, and processes for the preparation of the compounds of formula (I).
• Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship
  作者：Stig Jönsson、Gunnar Andersson、Tomas Fex、Tomas Fristedt、Gunnar Hedlund、Karl Jansson、Lisbeth Abramo、Ingela Fritzson、Olga Pekarski、Anna Runström、Helena Sandin、Ingela Thuvesson、Anders Björk

  DOI：10.1021/jm031044w

  日期：2004.4.1

  Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).